title: Permanent reduction of seizure threshold in post-ischemic CA3 pyramidal neurons.
abstract: The effects of ischemia were examined on CA3 pyramidal neurons recorded in hippocampal slices 2-4 mo after a global forebrain insult. With intracellular recordings, CA3 post-ischemic neurons had a more depolarized resting membrane potential but no change of the input resistance, spike threshold and amplitude, fast and slow afterhyperpolarization (AHP) or ADP, and firing properties in response to depolarizing pulses. With both field and whole-cell recordings, synaptic responses were similar in control and post-ischemic neurons. Although there were no spontaneous network-driven discharges, the post-ischemic synaptic network had a smaller threshold to generate evoked and spontaneous synchronized burst discharges. Thus lower concentrations of convulsive agents (kainate, high K(+)) triggered all-or-none network-driven synaptic events in post-ischemic neurons more readily than in control ones. Also, paired-pulse protocol generates, in post-ischemics but not controls, synchronized field burst discharges when interpulse intervals ranged from 60 to 100 ms. In conclusion, 2-4 mo after the insult, the post-ischemic CA3 pyramidal cells are permanently depolarized and have a reduced threshold to generate synchronized bursts. This may explain some neuropathological and behavioral consequences of ischemia as epileptic syndromes observed several months to several years after the ischemic insult.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale U 29, INMED, 13273 Marseille Cedex 09, France.
authors.forename: P
authors.initials: P
authors.lastname: Congar
authors.forename: J L
authors.initials: JL
authors.lastname: Gaïarsa
authors.forename: T
authors.initials: T
authors.lastname: Popovici
authors.forename: Y
authors.initials: Y
authors.lastname: Ben-Ari
authors.forename: V
authors.initials: V
authors.lastname: Crépel
mesh_terms: D018750:6-Cyano-7-nitroquinoxaline-2,3-dione / Q000494:pharmacology; D000200:Action Potentials / Q000187:drug effects / Q000502:physiology; D000818:Animals; D002545:Brain Ischemia / Q000150:complications / Q000503:physiopathology*; D004827:Epilepsy / Q000209:etiology / Q000503:physiopathology*; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D019706:Excitatory Postsynaptic Potentials / Q000187:drug effects / Q000502:physiology; D006624:Hippocampus / Q000166:cytology / Q000503:physiopathology*; D066298:In Vitro Techniques; D007608:Kainic Acid / Q000494:pharmacology; D008297:Male; D018408:Patch-Clamp Techniques; D010507:Periodicity; D011188:Potassium / Q000494:pharmacology; D017966:Pyramidal Cells / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D012640:Seizures / Q000209:etiology / Q000503:physiopathology; D013268:Stimulation, Chemical; D013569:Synapses / Q000502:physiology; D013997:Time Factors
chemical_list: D018690:Excitatory Amino Acid Agonists; D018691:Excitatory Amino Acid Antagonists; D018750:6-Cyano-7-nitroquinoxaline-2,3-dione; D011188:Potassium; D007608:Kainic Acid